Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"SPARC","sponsor":"Tripoint Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sparc Licenses Commercialization Rights of Elepsia Drug to Tripoint Therapeutics","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Addex Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study\u2019s Independent Interim Review Committee Recommends Continuing Study","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Levetiracetam Oral Solution","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Strides Receives USFDA Approval for Levetiracetam Oral Solution","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Levetiracetam

    Menu

    Levetiracetam

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Strides Pharma Science

              Contact Supplier
              • Development Update
              Virtual BoothStrides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Strides Receives USFDA Approval for Levetiracetam Oral Solution

              Details:

              USFDA approved generic version of Levetiracetam for the treatment of seizures. It prevents seizure activity via the selective inhibition of hypersynchronized epileptiform burst firing without affecting normal neuronal transmission.

              Lead Product(s): Levetiracetam

              Therapeutic Area: Neurology Product Name: Keppra-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 21, 2023

              Strides Pharma Science

              CPhI Worldwide, Milan

              Booth #5C33

              envelop Contact Supplier

              Strides Pharma Science

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Strides Receives USFDA Approval for Levetiracetam Oral Solution

              Details:

              Levetiracetam tablet is belongs to a class of drugs known as anticonvulsants, is indicated for adjunctive therapy in the treatment of Partial onset seizures in patients one month of age and older with epilepsy.

              Lead Product(s): Levetiracetam

              Therapeutic Area: Neurology Product Name: Keppra-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Addex Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

              Details:

              ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.

              Lead Product(s): ADX71149,Levetiracetam

              Therapeutic Area: Neurology Product Name: ADX71149

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Addex Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024

              Details:

              ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.

              Lead Product(s): ADX71149,Levetiracetam

              Therapeutic Area: Neurology Product Name: ADX71149

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 05, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Addex Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study

              Details:

              ADX71149/JNJ-40411813, is a selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive allosteric modulator (PAM) is in a Phase 2 clinical trial for the treatment of epilepsy.

              Lead Product(s): ADX71149,Levetiracetam

              Therapeutic Area: Neurology Product Name: ADX71149

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Johnson & Johnson Innovative Medicine

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1

              Details:

              ADX71149 (JNJ-40411813) is a novel orally active positive allosteric modulator of metabotropic Glutamate 2 receptor (mGlu2R). It is being developed for the treatment of epilepsy.

              Lead Product(s): ADX71149,Levetiracetam

              Therapeutic Area: Neurology Product Name: ADX71149

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Addex Therapeutics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SPARC

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sparc Licenses Commercialization Rights of Elepsia Drug to Tripoint Therapeutics

              Details:

              Under terms of the license agreement, SPARC will be eligible to receive tiered royalties ranging from 15% to 50% on net sales. Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA fees for ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg.

              Lead Product(s): Levetiracetam

              Therapeutic Area: Neurology Product Name: Elepsia

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Tripoint Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement September 22, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              DRL Levetiracetam RMB
              IOL Levetiracetam
              Close
              4
              Post Enquiry
              POST ENQUIRY